floxuridine has been researched along with Cancer of Kidney in 40 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "Floxuridine dosages were escalated to a maximum of 0." | 2.69 | Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study. ( Church, CK; DePriest, CB; Honeycutt, PJ; Schulof, RS; Soori, GS; Stark, JJ; Wiemann, MC, 1999) |
| "Metastatic renal cell carcinoma patients with measurable disease entered the study." | 2.68 | Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. ( Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Giulianotti, PC; Lencioni, M; Mosca, F; Pfanner, E; Ricci, S; Vannucci, L, 1996) |
| "Metastatic renal cell carcinoma (RCC) is largely chemoresistant." | 2.67 | A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Wilkinson, MJ, 1994) |
| "The initial dosage was 0." | 2.67 | A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Venook, AP; Wilkinson, MJ, 1993) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | 2.41 | Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "Gemcitabine was rapidly eliminated from plasma even in patients with renal dysfunction." | 1.35 | Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. ( Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T, 2008) |
| "The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR)." | 1.28 | [Adjuvant chemotherapy]. ( Buzzetti, V; Cogni, M; Del Nero, A; Longo, G; Mandressi, A; Mangiarotti, B; Russo, R, 1991) |
| "A total of 42 patients with metastatic renal cell carcinoma received floxuridine infusion for 14 days at monthly intervals." | 1.28 | Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. ( Amato, R; Dexeus, FH; Kilbourn, R; Kwan, J; Logothetis, CJ; Newman, RA; Ogden, S; Sella, A; Striegel, A, 1991) |
| "The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR)." | 1.28 | Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. ( Bonalumi, MG; Comeri, G; Damascelli, B; Del Nero, A; Garbagnati, F; Lutman, R; Marchianò, A; Mauri, M; Salvetti, M; Spreafico, C, 1990) |
| " Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index." | 1.27 | Phase II clinical evaluation of doxifluridine. ( Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986) |
| "Our results indicate that metastatic renal cell cancer responds to infusional chemotherapy and that the circadian shape of infusion markedly affects our ability to deliver effective doses." | 1.27 | Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. ( Fraley, EE; Hrushesky, WJ; Rabatin, JT; Von Roemeling, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.00) | 18.7374 |
| 1990's | 24 (60.00) | 18.2507 |
| 2000's | 10 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| Wang, HJ | 1 |
| Wang, H | 1 |
| Li, HZ | 1 |
| Shi, BB | 1 |
| Song, ZL | 1 |
| Stadler, WM | 2 |
| Ikemoto, S | 1 |
| Sugimura, K | 1 |
| Yoshida, N | 1 |
| Kuratsukuri, K | 1 |
| Wada, S | 1 |
| Nakatani, T | 1 |
| Gore, ME | 1 |
| Escudier, B | 1 |
| Masumori, N | 1 |
| Kunishima, Y | 1 |
| Hirobe, M | 1 |
| Takeuchi, M | 1 |
| Takayanagi, A | 1 |
| Tsukamoto, T | 1 |
| Itoh, T | 1 |
| Chu, SI | 1 |
| Kim, HJ | 1 |
| Skubitz, KM | 1 |
| Wong, MK | 1 |
| Bjarnason, GA | 2 |
| Hrushesky, WJ | 8 |
| Webster, P | 1 |
| Morava-Protzner, I | 1 |
| Towers, M | 1 |
| Small, EJ | 3 |
| Frye, JW | 2 |
| Wilkinson, MJ | 2 |
| Carroll, PR | 2 |
| Ernest, ML | 2 |
| Stagg, RJ | 2 |
| Falcone, A | 2 |
| Cianci, C | 2 |
| Ricci, S | 2 |
| Brunetti, I | 2 |
| Bertuccelli, M | 1 |
| Conte, PF | 2 |
| Conroy, T | 1 |
| Geoffrois, L | 1 |
| Guillemin, F | 1 |
| Luporsi, E | 1 |
| Krakowski, I | 1 |
| Spaëth, D | 1 |
| Frasie, V | 1 |
| Volff, D | 1 |
| Venook, AP | 1 |
| Doyle, N | 1 |
| Sone, M | 1 |
| Beattie, K | 1 |
| Elia, J | 1 |
| Owens, B | 1 |
| Garufi, C | 1 |
| Lévi, F | 1 |
| Giunta, S | 1 |
| Aschelter, A | 1 |
| Pace, R | 1 |
| Nisticò, C | 1 |
| Terzoli, E | 1 |
| Pfanner, E | 1 |
| Lencioni, M | 1 |
| Giulianotti, PC | 1 |
| Vannucci, L | 1 |
| Mosca, F | 1 |
| Hirano, Y | 3 |
| Takayama, T | 2 |
| Ushiyama, T | 3 |
| Suzuki, K | 3 |
| Fujita, K | 3 |
| Soori, GS | 1 |
| Schulof, RS | 1 |
| Stark, JJ | 1 |
| Wiemann, MC | 1 |
| Honeycutt, PJ | 1 |
| Church, CK | 1 |
| DePriest, CB | 1 |
| Yonekura, K | 2 |
| Basaki, Y | 2 |
| Chikahisa, L | 2 |
| Okabe, S | 2 |
| Hashimoto, A | 2 |
| Miyadera, K | 2 |
| Wierzba, K | 2 |
| Yamada, Y | 2 |
| Reese, DM | 1 |
| Corry, M | 1 |
| Morita, T | 1 |
| Matsuzaki, A | 1 |
| Tokue, A | 1 |
| Aoyagi, K | 1 |
| Kobayashi, M | 1 |
| Wood, PA | 1 |
| Kageyama, S | 1 |
| Carter, SK | 1 |
| Wasserman, TH | 1 |
| Vogelzang, NJ | 1 |
| Vokes, EE | 1 |
| Charette, J | 1 |
| Whitman, G | 1 |
| Zhang, ZG | 1 |
| Rustum, YM | 1 |
| Balletto, N | 1 |
| Cavallini, M | 1 |
| Cortesi, E | 1 |
| Decian, F | 1 |
| Arnone, GB | 1 |
| Civalleri, D | 1 |
| Del Nero, A | 2 |
| Mandressi, A | 1 |
| Longo, G | 1 |
| Cogni, M | 1 |
| Mangiarotti, B | 1 |
| Buzzetti, V | 1 |
| Russo, R | 1 |
| Dexeus, FH | 1 |
| Logothetis, CJ | 1 |
| Sella, A | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Ogden, S | 1 |
| Striegel, A | 1 |
| Kwan, J | 1 |
| Newman, RA | 1 |
| Damascelli, B | 2 |
| Marchianò, A | 2 |
| Frigerio, LF | 1 |
| Salvetti, M | 2 |
| Spreafico, C | 2 |
| Garbagnati, F | 2 |
| Zanoni, F | 1 |
| Radice, F | 1 |
| Lutman, R | 1 |
| Bonalumi, MG | 1 |
| Mauri, M | 1 |
| Comeri, G | 1 |
| von Roemeling, R | 4 |
| Lanning, RM | 1 |
| Rabatin, JT | 3 |
| Inaba, M | 1 |
| Mitsuhashi, J | 1 |
| Ozawa, S | 1 |
| Hurteloup, P | 1 |
| Armand, JP | 1 |
| Cappelaere, P | 1 |
| Metz, R | 1 |
| Kerbrat, P | 1 |
| Keiling, R | 1 |
| Fumoleau, P | 1 |
| Fargeot, P | 1 |
| Schraub, S | 1 |
| Bastit, P | 1 |
| Fraley, EE | 2 |
3 reviews available for floxuridine and Cancer of Kidney
| Article | Year |
|---|---|
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
Circadian chemotherapy for gynecological and genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm; | 2002 |
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F | 1991 |
13 trials available for floxuridine and Cancer of Kidney
| Article | Year |
|---|---|
[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2004 |
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1994 |
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Floxurid | 1993 |
Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedul | 1993 |
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Diarrhea; Drug Administrati | 1993 |
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom | 1995 |
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1996 |
Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 1999 |
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carci | 1992 |
Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedule; Drug Evaluat | 1991 |
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Female; Floxuridine; Humans; Infusion Pumps; K | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Implants | 1989 |
24 other studies available for floxuridine and Cancer of Kidney
| Article | Year |
|---|---|
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials | 2004 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2004 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal | 2008 |
Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine.
Topics: Aged; Carcinoma, Renal Cell; Floxuridine; Humans; Infusions, Intravenous; Kidney Neoplasms; Lung Dis | 1995 |
Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.
Topics: Aged; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Floxuridine; Forced Expiratory Volume; H | 1995 |
Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedu | 1995 |
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Screening Assays | 1998 |
[Interferons alpha-2a and gamma increase the antitumor activity, detected by histoculture drug response assay, of doxifluridine against clinical renal cell cancers].
Topics: Antineoplastic Agents; Cell Death; Drug Screening Assays, Antitumor; Drug Synergism; Floxuridine; Hu | 1999 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2000 |
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxyc | 2001 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Floxuridine; Fluorouracil; Humans; Kidney; K | 2002 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms.
Topics: Cecal Neoplasms; Drug Administration Schedule; Drug Synergism; Floxuridine; Humans; Ileal Neoplasms; | 1992 |
[Clinical use of a totally implantable and programmable pump for the infusion of drugs].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Humans; Infusion Pumps, Implantable; Kidne | 1992 |
[Adjuvant chemotherapy].
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Floxuridine; Follow-Up Studies; Hu | 1991 |
Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Floxuridine; Humans; Infus | 1991 |
Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Evaluation; Female; Floxuridine; Humans; Infusion Pumps, Im | 1990 |
Kinetic analysis of 5-fluorouracil action against various cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Flo | 1990 |
Phase II clinical evaluation of doxifluridine.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col | 1986 |
Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Floxuridine; Gastrointestinal Diseases; Humans; Infusion | 1988 |
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Flox | 1988 |